Amgen (AMGN) Receives News Sentiment Rating of 0.37

News articles about Amgen (NASDAQ:AMGN) have trended positive on Sunday, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Amgen earned a news impact score of 0.37 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 82 out of 100, meaning that recent press coverage is very likely to have an impact on the stock’s share price in the immediate future.

These are some of the news stories that may have effected Accern Sentiment’s rankings:

Insider Buying and Selling by Quarter for Amgen (NASDAQ:AMGN)

A number of equities analysts have recently commented on AMGN shares. Jefferies Group LLC downgraded shares of Amgen from a “buy” rating to a “hold” rating and cut their target price for the company from $194.00 to $180.00 in a research note on Wednesday, April 5th. Vetr raised shares of Amgen from a “buy” rating to a “strong-buy” rating and set a $184.82 price target on the stock in a research note on Monday, March 27th. Credit Suisse Group reaffirmed a “hold” rating and set a $178.00 price target on shares of Amgen in a research note on Tuesday, April 4th. Cowen and Company reaffirmed an “outperform” rating and set a $209.00 price target on shares of Amgen in a research note on Wednesday, April 19th. Finally, Mizuho set a $195.00 price target on shares of Amgen and gave the stock a “buy” rating in a research note on Thursday, March 16th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, ten have assigned a buy rating and three have issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $184.94.

Amgen (AMGN) opened at 172.50 on Friday. Amgen has a 1-year low of $133.64 and a 1-year high of $184.21. The firm’s 50-day moving average is $160.31 and its 200-day moving average is $161.40. The firm has a market capitalization of $126.86 billion, a price-to-earnings ratio of 16.38 and a beta of 1.37. Amgen also was the target of unusually large options trading activity on Thursday. Traders acquired 1,115 put options on the stock. This is an increase of approximately 182% compared to the typical daily volume of 396 put options.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, April 26th. The medical research company reported $3.15 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.00 by $0.15. Amgen had a net margin of 34.42% and a return on equity of 29.37%. The business had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.60 billion. During the same quarter in the prior year, the firm earned $2.90 EPS. The firm’s quarterly revenue was down 1.1% compared to the same quarter last year. On average, equities analysts anticipate that Amgen will post $12.44 EPS for the current year.

In other news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the sale, the senior vice president now owns 24,214 shares of the company’s stock, valued at approximately $3,738,641.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION WARNING: “Amgen (AMGN) Receives News Sentiment Rating of 0.37” was originally posted by sleekmoney and is owned by of sleekmoney. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *